[Final recommendations to incorporate efalizumab into the clinical practice]

Actas Dermosifiliogr. 2008 Jan:99 Suppl 1:82. doi: 10.1016/s0001-7310(08)76202-1.
[Article in Spanish]
No abstract available

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Biological Products / adverse effects
  • Biological Products / therapeutic use*
  • Dermatologic Agents / adverse effects
  • Dermatologic Agents / therapeutic use*
  • Humans
  • Professional Practice
  • Psoriasis / drug therapy
  • Psoriasis / therapy*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Biological Products
  • Dermatologic Agents
  • efalizumab